Search | Clinical Trials Finder

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Asthma
Interventions: Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder, Placebo; Drug
Lead sponsor: West-Ward Pharmaceutical; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol, fluticasone propionate, montelukast; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 80
States / cities: Ozark, Alabama • Tempe, Arizona • Little Rock, Arkansas + 67 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 8
States / cities: DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more

Conditions: COPD
Interventions: Placebo, Fluticasone /salmeterol; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone propionate/salmeterol combination product, Salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 39
States / cities: Jasper, Alabama • Mobile, Alabama • Los Angeles, California + 35 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg, Placebo only; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 24
States / cities: Jasper, Alabama • Phoenix, Arizona • Long Beach, California + 20 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: FF, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 8
States / cities: San Diego, California • Baltimore, Maryland • Wheaton, Maryland + 5 more

Conditions: Smoking
Interventions: echocardiogram plus albuterol, airway blood flow plus albuterol, Fluticasone propionate, placebo; Procedure · Drug
Lead sponsor: University of Miami; Other
Eligibility: 25 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250, Formoterol fumarate 10; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 62
States / cities: Pell City, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more

Conditions: Obstructive Sleep Apnea Syndrome
Interventions: Nasal Fluticasone, Placebo; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 12 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 17
States / cities: Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 13 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 6,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 190
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more

Conditions: Sleep Apnea, Chronic Nasal Congestion
Interventions: Oxymetazoline Hydrochloride, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Asthma
Interventions: Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more

Conditions: Persistent Asthma
Interventions: Formoterol 12 mcg, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg, Fluticasone propionate 500 mcg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 827 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 27
States / cities: Avondale, Arizona • North Hollywood, California • Bradenton, Florida + 21 more

Conditions: Eosinophilic Esophagitis
Interventions: Fluticasone, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Asthma
Interventions: MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Placebo; Drug
Lead sponsor: Mylan Pharma UK Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more

Conditions: Eosinophilic Esophagitis
Interventions: Retrospective evaluation of endoscopy prior to study drug, Symptom Survey, Medication Compliance Phone Call, Endoscopy while on study drug, Fluticasone, Omeprazole, Placebo oral capsule; Diagnostic Test · Other · Drug
Lead sponsor: Claire Daniels; Federal
Eligibility: 6 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, VI, UMEC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more

Conditions: Eustachian Tube Dysfunction
Interventions: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ADVAIR DISKUS™ 250/50mcg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 21 more

Search by objective public record fields.

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

Study Of Patients With Allergic Rhinitis And Asthma

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Steroids for Pediatric Apnea Research in Kids

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

Study of Safety of Foradil in Patients With Persistent Asthma

Topical Steroid Treatment for Eosinophilic Esophagitis

MGR001 / Advair Diskus Local Equivalence Study in Asthma

EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)